I-Myeloma eminingi ene-Extramedullary Plasmacytoma

Lokhu kuyindaba yesiguli esineminyaka engu-73 ubudala esitholakale sine-myeloma eminingi, eyinkimbinkimbi ukuba khona kwe-extramedullary plasmacytoma. Kuyo yonke inkambo yokwelashwa nge-Dara-VRD (i-Daratumumab, i-Bortezomib, i-Lenalidomide, i-Dexamethasone), i-extramedullary plasmacytoma yaqhubeka, ibangela ubuhlungu obukhulu nokungahambi kahle esigulini.

Uma kucatshangelwa uhlobo olunolaka lwalesi sifo kanye nokuntuleka kokuphendula emithini yokwelapha evamile, isiguli sabhaliswa esivivinyweni somtholampilo se-BCMA CAR-T cell therapy. Ngemva kokubhekana nezinyathelo ezidingekayo zokulungiselela, okuhlanganisa nokuqedwa kwe-lymphodepletion, isiguli sathola ukumnika amaseli e-BCMA CAR-T.

Ngokuphawulekayo, phakathi kwezinsuku ezingu-10 ngemva kokumnika, isiguli sathola impendulo ye-second-degree cytokine release syndrome (CRS), ebonisa ukusebenza okuqinile kokuzivikela komzimba. Ukwengeza, bekukhona i-CRS yendawo ebalulekile endaweni ye-extramedullary plasmacytoma.

Okumangaza nakakhulu ukuthi phakathi nalesi sikhathi esifushane, isilonda se-extramedullary esimelana nokwelashwa ngaphambili, esasibonakale simelana nemigqa eminingi yokwelashwa ngamakhemikhali, izinto ezihlosiwe, namasosha omzimba e-monoclonal, sanyamalala ngokuphelele. Isiguli sathola ukuxolelwa okuphelele, okuphawula impumelelo yokwelashwa.

Kuyo yonke inqubo yokwelapha, ithimba lezokwelapha laliqaphe ngokucophelela isiguli ukuze libone noma yiziphi izimpawu zokusabela okungekuhle futhi linikeze ukunakekelwa okubanzi okusekelayo. Lokhu kwakuhlanganisa ukuphatha izimpawu ze-CRS kanye nokubhekana nanoma yiziphi ezinye izinkinga ezihlobene nokwelashwa.

Njengoba ukwelashwa kuqhubeka, ithimba lezokwelapha laqhubeka nokuqapha ngokucophelela ukusabela kwesiguli ekwelashweni kweseli ye-BCMA CAR-T. Ukuhlola okuvamile kwenziwa ukuze kuhlolwe ukusebenza kokwelashwa kanye nokubhekana nanoma yimiphi imiphumela emibi evelayo ngokushesha.

Ukulandela impumelelo ephawulekayo yokuxolelwa okuphelele, izinga lokuphila lesiguli liye lathuthuka kakhulu, ngokukhululeka kobuhlungu nokungakhululeki okuhambisana ne-extramedullary plasmacytoma. Njengoba lesi sifo silawulwa, isiguli sakwazi ukuqhubeka nemisebenzi yansuku zonke futhi sijabulele ukuba nempilo engcono.

Ngaphezu kwalokho, ngokubona ukubaluleka kokunakekelwa kokulandelela isikhathi eside, ithimba lethu lezokwelapha lahlala libambe iqhaza ohambweni lwangemva kokwelashwa kwesiguli. Ukuqokwa kokulandelela okuvamile kwakuhlelelwe ukuqapha isimo sesiguli, ukuhlola ukuqina kwempendulo yokwelashwa, futhi kubhekwane nanoma yikuphi ukuphindeka okungase kube khona noma imiphumela engemihle engase ifike sekwephuzile.

Ngaphezu kokulandelelwa kwezempilo, isikhungo sethu sinikeze izinsiza eziphelele zokusekela ukuze sisize isiguli ukuthi sijwayele ukuphila ngemva kokwelashwa. Lokhu kuhlanganisa ukufinyelela ezinsizeni zokwelulekwa, izinhlelo zokuhlunyeleliswa, kanye nezinsiza zemfundo ukusiza isiguli nomndeni waso ukuthi bazulazule ekusindeni futhi bagcine indlela yokuphila enempilo.

Umphumela oyimpumelelo waleli cala awubonisi nje kuphela ukusebenza kahle kwe-BCMA CAR-T cell therapy ekwelapheni i-myeloma eminingi ephikisayo kodwa futhi igqamisa ukubaluleka kokunakekelwa komuntu siqu kanye nemikhakha eminingi ekulawuleni izifo eziyinkimbinkimbi ze-hematological. Ukuzibophezela kwethu ekuhlinzekeni ukusekela okuqhubekayo nokunakekelwa kokulandelela kubonisa ukuzinikela kwethu ekuqinisekiseni imiphumela engcono kakhulu yeziguli zethu ngale kwesigaba sokwelashwa.

Ngaphambi kanye nezinyanga ezi-3 ngemuva kokumnika